Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Turn Therapeutics Inc (TTRX)

29 + Investors. Track Smart Money conviction in TTRX. See who's accumulating, reducing, or initiating positions.

Fetching live quote...
Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +9
Streak
1Q ▲
Buyers last Q
79%

Smart Money Signals — TTRX

Based on 29 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 2Q
For 1 consecutive quarter, more hedge funds added TTRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (100% of max)

100% of all-time peak
29 hedge funds hold TTRX right now — the highest count in 0.8 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🟢

More buyers than sellers — 79% buying

15 buying4 selling
Last quarter: 15 funds were net buyers (11 opened a brand new position + 4 added to an existing one). Only 4 were sellers (2 trimmed + 2 sold completely). A clear majority buying is a strong confirmation signal.
📈

More new buyers each quarter (+8 vs last Q)

new funds entering per quarter
Funds opening a new TTRX position: 3 → 11. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔄

Mostly new holders — 100% entered in last year

■ 0% conviction (2yr+) ■ 0% medium ■ 100% new
Only 0 funds (0%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.
💰

Value +474% but shares only +150% — price-driven

Value
+473%
Shares
+150%
Last quarter: the total dollar value of institutional holdings rose +474%, but actual share count only changed +150%. The gap is explained by the stock's price rising — not new buying. Strong value growth with weak share growth means the rally is price momentum, not fresh institutional demand.
🌱

Early stage — 100% of holders entered in last year

■ 0% veterans ■ 0% 1-2yr ■ 100% new
Of 29 current holders: 29 (100%) entered in the past year, only 0 (0%) are 2+ year veterans. This is an early-phase institutional idea — still being discovered. High upside potential if the thesis plays out, but thin conviction base.
📋

Smaller funds dominant — 18% AUM from top-100

18% from top-100 AUM funds
10 of 29 holders rank in the top 100 by AUM, but together hold only 18% of total institutional value. The stock is held primarily by smaller and mid-sized funds.
5.5
out of 10
Moderate Exit Risk
Exit risk score 5.5/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — TTRX

In 2026 Q2, 15 hedge funds were net buyers of TTRX (11 opened a new position, 4 added to an existing one), while 4 reduced or exited (2 trimmed, 2 sold completely) — a 79% buyer ratio, indicating clear institutional accumulation. Net fund flow last quarter: +9 funds (more new holders than closures). Total institutional holders: 29.

Hedge Fund Ownership: TTRX

How many hedge funds hold TTRX — quarterly history vs. share price
Quarterly hedge fund ownership of TTRX vs. share price

Market Analysis: TTRX

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: TTRX

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Turn Therapeutics Inc (TTRX) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much TTRX has moved relative to its sector benchmark (XLV) since the 2026 Q3 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End September 30, 2026 · 48d ago
TTRX
-40.6%
XLV
+9.8%

TTRX outperformed XLV by -50.4% since September 30, 2026.

Since 13F Filing Date November 14, 2026 · 3d ago
TTRX
-8.5%
XLV
-2.1%

Since the filing became public, TTRX outperformed XLV by -6.4% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

3 top-rated funds 0 high-conviction
Consensus
2.6
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: TTRX
2026 Q3 Stats Unlock in 2 days 29 + Investors

Track Smart Money conviction in TTRX. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q2) Prior (2026 Q1) Change
Funds Holding 29 20 45.0%
13F Shares 1M 462K 150.17%
Total Value $8M $1M 473.52%
New Positions 11 3 +8
Increased Positions 4 3 +1
Closed Positions 2 5 -3
Reduced Positions 2 2 -
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: TTRX

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q3)

29 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in TTRX. Verified SEC 13F-HR filings.

QUARTER:
2026 Q3 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.
Top 25 TTRX holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 DDFG, Inc 0.32% 111,379 $1.6M
2 McCarthy Asset Management, Inc. 0.10% 15,018 $216K
3 SteelPeak Wealth, LLC 0.09% 251,275 $3.6M
4 Tamar Securities, LLC 0.04% 30,000 $432K
5 Aster Capital Management (DIFC) Ltd 0.03% 5,235 $75K
6 Aaron Wealth Advisors LLC 0.02% 32,564 $469K
7 Cannon Financial Strategists, Inc. 0.02% 10,000 $144K
8 Ieq Capital, LLC 0.01% 227,396 $3.3M
9 Jefferies Financial Group Inc. 0.00% 16,300 $235K
10 Composition Wealth, LLC 0.00% 10,000 $144K
11 Jump Financial, LLC 0.00% 14,944 $215K
12 Brown Brothers Harriman & Co 0.00% 23,688 $341K
13 Hrt Financial LP 0.00% 57,450 $826K
14 Pflug Koory, LLC 0.00% 170 $2K
15 Millennium Management LLC 0.00% 167,802 $2.4M
16 HighTower Advisors, LLC 0.00% 24,279 $349K
17 Blue Trust, Inc. 0.00% 1,122 $16K
18 Vanguard Capital Management LLC 0.00% 423,893 $6.1M
19 Qube Research & Technologies Ltd 0.00% 10,941 $157K
20 Vanguard Fiduciary Trust Co 0.00% 36,048 $519K
21 TD Waterhouse Canada Inc. 0.00% 3,059 $40K
22 Morgan Stanley 0.00% 139,674 $2.0M
23 BlackRock, Inc. 0.00% 259,028 $3.7M
24 LPL Financial LLC 0.00% 16,100 $232K
25 Barclays plc 0.00% 13,748 $198K
Investor Ownership
History
% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Turn Therapeutics Inc (TTRX)

What does the Smart Money Trend signal show for TTRX?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added TTRX than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for TTRX?

More buyers than sellers — 79% buying: Last quarter: 15 funds were net buyers (11 opened a brand new position + 4 added to an existing one). Only 4 were sellers (2 trimmed + 2 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for TTRX holders?

Smaller funds dominant — 18% AUM from top-100: 10 of 29 holders rank in the top 100 by AUM, but together hold only 18% of total institutional value. The stock is held primarily by smaller and mid-sized funds.

How long have hedge funds held TTRX?

Mostly new holders — 100% entered in last year: Only 0 funds (0%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Turn Therapeutics Inc (TTRX) following the 2026 Q3 hedge fund 13F filings?

As of today, TTRX has moved -8.5% since the 2026 Q3 13F filing date (November 14, 2026), compared to -2.1% for the XLV sector ETF — an outperformance of -6.4%. Since the quarter end (September 30, 2026), TTRX has gained -40.6% vs +9.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →